Experts have raised concerns about Quest Diagnostics’ $399 consumer-initiated Alzheimer’s disease test, telling 360Dx that it is unclear whether the product is accurate enough to support its use.

Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry, has announced a partnership with leading Alzheimer’s genomics expert Dr. Carlos Cruchaga to explore the role of circRNAs as blood biomarkers for early diagnosis and treatment of Alzheimer’s Disease.

The Alzheimer’s disease blood test developer C2N Diagnostics has released a new version of its screener for beta amyloid proteins, and it’s gearing up for a nationwide rollout as public hopes rise for treatments that may make some headway against the condition.

Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's disease protein that can appear years before dementia symptoms arise.

GE HealthCare raised its profit forecasts for 2023 after recording better-than-expected financials in its Q2 earnings report.

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

New research has uncovered protein signatures associated with different forms of Alzheimer's disease (AD), including markers found in plasma, cerebrospinal fluid (CSF), and brain tissue.

Roche said Tuesday that it secured US Food and Drug Administration 510(k) clearances for a pair of assays to aid diagnosis of Alzheimer's disease measuring levels of beta-amyloid and tau proteins.

Alzheimer's disease (AD) is a common neurodegenerative disease that affects the cognitive and memory abilities of the brain.

C2N Diagnostics announced the publication of a study further confirming the sensitivity of its PrecivityAD blood test for diagnosing Alzheimer’s disease.